Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Importance of Therapeutic Monitoring of Orally Administered Disease-modifying Drugs Used in the Treatment of Multiple Sclerosis

NCT05112484 is registered in ClinicalTrials.gov with University Hospital Ostrava as lead sponsor.

NCT NCT05112484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05112484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Importance of Therapeutic Monitoring of Orally Administered Disease-modifying Drugs Used in the Treatment of Multiple Sclerosis
Lead sponsor
University Hospital Ostrava
Phase
Observational
Overall status
Unknown status
Start date
June 30, 2024
Completion date
May 31, 2026
Enrollment
600 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis